本研究使用穿顱超音波儀器(Transcranial Doppler, TCD)作爲工具，用以評估經補陽還五湯加減方〈Buyanghuanwu-Tang add-on decoction〉治療的缺血性中風病人，早期大腦血液動力學的改變與其預後的關係。初次因中大腦動脈灌注區缺血性中風的病人，只要是發生在72小時內的病患皆納入本研究中。採用補陽還五湯加減方的病患，從住院的第一天開始即持績給與3個月的治療；並且於住院的第一天及住院後的第7天，分別使用穿顱超音波儀器(Transcranial Doppler, TCD)，檢查其收縮血流速度(Systolic Blood Flow Velocity, Vsys.)、平均血流速度(Mean Blood Flow Velocity, Vmean)、持動性指數(Pulsatility Index, PI)及阻力性指數(Resistance Index, RT)的改變。我們也使用CNS(Canadian Neurological Scale)，及NIHSS (National Institudes of Health of stroke score)評估這些病患神經學缺損的程度，並於住院的第一天、第7天及3個月後分別作下記錄。結果發現在補陽還五湯加減方治療的病患組群中比未使用的，其大腦血液動力學的變化有更明顯的改善。神經缺損的評估記錄中，也發現使用補陽還五湯加減方治療的病患組群比未使用的，於3個月後的神經缺損狀況也有明顯地政善。我們的結論認爲“補陽還五湯加減方在早期中大腦動脈缺血性中風的病人，使用上是安全有效的；亦或可作爲替代基因重組型人組織纖溶酶原激活劑〈recombinant human tissue-type plasminogen activator, rt-PA〉不能使用在超過3小時後的缺血性中風患者身上的缺憾；而早期使用穿顱超音波儀器(Transcranial Doppler, TCD)評估大腦缺血性中風病患的血液動力改變的情況，可作爲往後神經功能恢復的預測。

The studies of using the Transcranial doppler 〈TCD〉 as a tool to evaluate the correlationship between the early cerebral vascular hemodynamic changes and the prognosis of ischemic stroke patients been treated by Buyanghuanwu-Tang add-on decoction were designed. All patients suffered from first attack of middle cerebral artery 〈MCA〉 territory ischemic stroke within 72 hours been enloaded into our studies. The patients were treated with Buyanghuanwu-Tang add-on decoction in the course of 3 months periods from the first admission day, and the systolic blood flow velocity 〈Vsys〉、mean blood flow velocity 〈Vmean〉、pulsatility index 〈PI〉 and resistance index 〈RI〉 were examined by transcranial doppler 〈TCD〉 on the first admission day and 7 days later seperatively. The CNS(Canadian Neurological Scale), and NIHSS (National Institudes of Health of stroke score) been used to evaluate the neurological deficits conditions of the patients on the first admission day and 7 days 3 months later in the following days More obviously improvement the cerebral vascular hemodynamics were noted on the 7 days post admission compared with that on the first admission day in the Buyanghuanwu-Tang add-on decoction treated patients group than that in the non-treated patients group Neurological deficits conditional score also were obviously improved when 3 months later since first admission day in the Buyanghuanwu-Tang add-on decoction treated patients group compared with that in the non-treated patients group Our conclusion in this studies is that Buyanghuanwu-Tang add-on decoction may be used safely and effectively in the early stage of acute middle cerebral vascular 〈MCA〉 territory ischemic stroke patients On the other's hand, Buyanghuanwu-Tang add-on decoction may be considered to play a replacement role of recombinant human tissue-type plasminogen activator 〈rt-PA〉 can't be used beyond the 3 hours after ischemic stroke attack The trancranial doppler (TCD) may be used as an useful tool to predict the future prognosis in the acute stage of the ischemic stroke patients.